Clinical Trial: Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer

U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07720167) titled 'Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer' on July 17.

Brief Summary: The study will investigate the role of cemiplimab in combination with platinum doublet chemotherapy in stage I resectable non-small cell lung cancer (NSCLC). Sub-4cm NSCLC tumors are highly lethal malignancies, yet no therapies are used in these patients to improve chances of survival with surgery alone. Here will be examined the ability of 3 cycles of cemiplimab-chemotherapy to induce pathologic complete responses to treatment.

Study Start Date: Nov. 01, 2026

Study Type: INTERVENTIONAL

Condition: Non-Small Cell Lung Cancer

Interven...